Entrada Therapeutics, Inc. (TRDA) will announce topline results from Cohort 1 of its phase 1/2 clinical study of ENTR-601-44 in Duchenne muscular dystrophy on Thursday, May 7, 2026.
Duchenne muscular dystrophy is a rare disease caused by mutations in the DMD gene, which encodes for the dystrophin protein essential to maintaining the structural integrity and function of muscle cells.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com